Clinical Trial Detail

NCT ID NCT03085095
Title A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO)
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Myovant Sciences GmbH
Indications

prostate adenocarcinoma

Therapies

Relugolix

Leuprolide

Age Groups: adult senior

No variant requirements are available.